Get started
Author

Vida Alami

Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
2023 · Chad G Rusthoven, Alyse W Staley, et al. · JNCI Journal of the National Cancer Institute · 29
PDF
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
2024 · Anthony D. Elias, Alyse W. Staley, et al. · npj Breast Cancer · 9
PDF
Risk of transfusion‐related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center
2024 · Shelby Winzent‐Oonk, Alyse Staley, et al. · Pediatric Blood & Cancer · 4
Survival and treatment trends in BRCA-mutated metastatic pancreatic adenocarcinoma.
2026 · Gabriel Haw, Vida Alami, et al. · Journal of Clinical Oncology · 1
PDF
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors
2025 · Alexander S. Watson, Alyse W. Staley, et al. · JTO Clinical and Research Reports · 1
The association of antibiotic use and survival among patients receiving first line immunotherapy-based treatment for advanced gastroesophageal cancers.
2025 · Nicole Baranda Balmaceda, Junxiao Hu, et al. · Journal of Clinical Oncology · 1
PDF
Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
2024 · Stephanie Lakritz, Andrew Nicklawsky, et al. · Clinical Genitourinary Cancer · 1
Integrated variant allele frequency analysis pipeline and R package: easyVAF
2023 · Junxiao Hu, Vida Alami, et al. · Molecular Carcinogenesis · 1
PDF
Perceptions of Proactive Palliative Care Integration Among Pediatric Hematopoietic Cell Transplant Providers: A Pilot Study
2026 · Sydney Ariagno, Vida Alami, et al. · Children
PDF
Cumulative toxicity assessed by area-under-the-curve (AUC) in targeted therapy versus chemotherapy for advanced EGFR -mutant NSCLC.
2026 · William J. Phillips, Vida Alami, et al. · Journal of Clinical Oncology
PDF
Real-world survival and responses to HER2 directed treatment in gastrointestinal cancers based on HER2 non-amplified mutation and HER2 amplification/overexpression status.
2026 · Nicole Baranda Balmaceda, Vida Alami, et al. · Journal of Clinical Oncology
Molecular profiling and potential therapeutic implications of molecular testing utilizing a large database of hepatocellular carcinoma patients.
2026 · Alexander Hayden, Vida Alami, et al. · Journal of Clinical Oncology
PDF
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide
2025 · Jennifer Richer, Anthony D. Elias, et al. · Clinical Cancer Research
P1.12B.08 Thrombotic Events at Diagnosis are Associated with Poorer First Line TKI Outcomes Among Metastatic ALK and ROS1 NSCLC Patients
2024 · M. Sakamoto, J. Hu, et al. · Journal of Thoracic Oncology
PDF
Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer
2023 · Anthony D. Elias, Alyse Staley, et al. · Cancer Research
Works count: 15
Citation count: 47
H-index: 3
I10-index: 1
Year
Topic
Type